Advanced/metastatic non-small cell lung cancer (NSCLC) research hub
3 indexed studies · 0 currently recruiting
- ongoing, recruitingTherapeutic confirmatory (Phase III)
TACTI-004, a double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (PD-1 antagonist) and chemotherapy.
This study is testing a new combination of treatments for advanced lung cancer. It combines a new drug, eftilagimod alfa, with existing treatments like pembrolizumab and chemotherapy, to see if it can help people live longer and improve their quality of life. Participants will be randomly assigned to different treatment groups.
Romania · Lithuania · Bulgaria - active not recruitingPHASE3
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
This study compares a new drug, TAK-788, with standard chemotherapy for advanced lung cancer (NSCLC) where the cancer has a specific genetic change (EGFR exon 20 insertion mutation). It's for people who haven't had prior treatment for their advanced cancer.
United States · Australia · Austria - active not recruitingPHASE3
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
This study is looking at a new treatment called efti, combined with standard care, for advanced lung cancer. It compares how well this combination works against the standard care alone to see if it helps people live longer and stops cancer from growing for longer. Participants will receive treatment for up to two years.
United States · Argentina · Australia